Enfuvirtide

This classification denotes an anti-hiv agent with the molecular formula C204H301N51O64, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19OWO1T3ZE, chemically known as l-phenylalaninamide, n-acetyl-l-tyrosyl-l-threonyl-l-seryl-l-leucyl-l-isoleucyl-l-histidyl-l-seryl-l-leucyl-l-isoleucyl-l-alpha-glutamyl-l-alpha-glutamyl-l-seryl-l-glutaminyl-l-asparaginyl-l-glutaminyl-l-glutaminyl-l-alpha-glutamyl-l-lysyl-l-asparaginyl-l-alpha-glutamyl-l-glutaminyl-l-alpha-glutamyl-l-leucyl-l-leucyl-l-alpha-glutamyl-l-leucyl-l-alpha-aspartyl-l-lysyl-l-tryptophyl-l-alanyl-l-seryl-l-leucyl-l-tryptophyl-l-asparaginyl-l-tryptophyl- but generally known as enfuvirtide, which bears US NIH Compound Identifier 16130199. European Medicines Agency schedules Enfuvirtide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12496MIG. The term ENFUVIRTIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). World Health Organization schedules enfuvirtide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule enfuvirtide under HS 29332990 and SITC 51573. As of Q4 2014, ENFUVIRTIDE remains the US FDA Preferred Term for this commodity. Enfuvirtide bears US NLM identifiers UMLS ID C0537439 and NCI Concept Code C2105. SMILES: O=C(NC(C(CC)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(C(=O)NC(CCC(=O)N)C(=O)NC(C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(Cc1c2c([nH]c1)cccc2)C(=O)NC(C(=O)NC(C(=O)NC(CC(C)C)C(=O)NC(Cc1c2c([nH]c1)cccc2)C(=O)NC(CC(=O)N)C(=O)NC(Cc1c2c([nH]c1)cccc2)C(=O)NC(Cc1ccccc1)C(=O)N)CO)C)CC(=O)O)CCC(=O)O)CCC(=O)N)CCC(=O)O)CC(=O)N)CCC(=O)O)CCC(=O)N)CC(=O)N)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C)Cc1ccc(O)cc1)C(O)C)CO)CC(C)C)C(CC)C)Cc1[nH]cnc1)CO)CC(C)C.